Translational Notes: GSK goes deep with DPAc


Table 1. GSK's Discovery Partnerships with Academia (DPAc) deals. Since launching the DPAc program in 2010, GlaxoSmithKline plc has partnered with nine academic teams to discover therapeutics for a wide range of indications.


Lead researcher



Fred Hutchinson Cancer Research Center

Stephen Tapscott

Musculoskeletal disease

Prevention of double homeobox 4 (DUX4)-mediated muscle atrophy in facioscapulohumeral muscular dystrophy (see Martz, L., SciBX 6(1); doi:10.1038/scibx.2013.2)

The Hospital for Sick Children

Christine Bear

Pulmonary disease

Potentiators/correctors of DF508-mutant cystic fibrosis transmembrane conductance regulator (CFTR) to treat cystic fibrosis (CF)

University of Cambridge

David Lomas

Endocrine/metabolic disease

Treatment of α1-antitrypsin (AAT; A1AT; SERPINA1) deficiency using small molecule stabilizers

University College London

Mark Pepys

Endocrine/metabolic disease

Treatment of transthyretin (TTR) amyloidosis using TTR stabilizers

University of Dundee

Irwin McLean


Treatments for recessive dystrophic epidermolysis bullosa (see
Haas, M.J., SciBX 4(25); doi:10.1038/scibx.2011.700)

University of Dundee

Susann Schweiger


Development of a disease-modifying approach to treat Huntington's disease (HD)

The University of Edinburgh

Damian Mole

Gastrointestinal disease

Prevention of multiple organ failure in severe acute pancreatitis

University of Paris Descartes

Alain Hovnanian


Topical therapy for Netherton syndrome, rosacea and atopic dermatitis

Vanderbilt University School of Medicine

Roger Cone

Endocrine/metabolic disease

Positive allosteric modulators (PAMs) of the melanocortin 4 receptor (MC4R) to treat severe obesity